Clinical trial
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
NCT02484547 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT02484547 |
|---|---|
| Title | 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease |
| Official title | A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease |
| Acronym | EMERGE |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Aducanumab (BIIB037), Placebo |
| Enrollment | 1,643 |
| Start date | Sep 15, 2015 |
| Primary completion | Aug 5, 2019 |
| Completion | Aug 5, 2019 |
| First posted | Jun 29, 2015 |
| Last update posted | Sep 2, 2021 |
| Countries | Belgium, Canada, Finland, France, Germany, Italy, Japan, Netherlands, Poland, Spain, Sweden, Switzerland and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: